Close Menu

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.

The Belgian Society of Medical Oncology has partnered with Illumina, OncoDNA, and PierianDx for this study, which will enroll 864 patients with advanced metastatic cancer.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.

The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.

The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.

The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.

The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.

The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.

The companies will develop a version of Illumina's TruSight 170 sequencing panel for two of Loxo's targeted oncology drugs.